Cidara Therapeutics Inc’s filing revealed that its Chief Medical Officer Davarpanah Nicole Negar unloaded Company’s shares for reported $29797.0 on Sep 11 ’25. In the deal valued at $62.86 per share,474 shares were sold. As a result of this transaction, Davarpanah Nicole Negar now holds 31,418 shares worth roughly $2.37 million.
Then, RA CAPITAL MANAGEMENT, L.P. bought 2,272,727 shares, generating $99,999,988 in total proceeds. Upon buying the shares at $44.00, the Director now owns 3,365,523 shares.
Before that, Mineo Chrysa bought 2,270 shares. Cidara Therapeutics Inc shares valued at $49,281 were divested by the Director at a price of $21.71 per share. As a result of the transaction, Mineo Chrysa now holds 2,270 shares, worth roughly $0.17 million.
A number of analysts have revised their coverage, including Citizens JMP’s analysts, who began to cover the stock in mid March with a ‘”a Mkt outperform”‘ rating. RBC Capital Mkts started covering the stock on December 13, 2024. It rated CDTX as “an Outperform”.
Price Performance Review of CDTX
On Monday, Cidara Therapeutics Inc [NASDAQ:CDTX] saw its stock jump 9.84% to $75.47. Over the last five days, the stock has gained 12.79%. Cidara Therapeutics Inc shares have risen nearly 549.48% since the year began. Nevertheless, the stocks have risen 180.77% over the past one year. While a 52-week high of $74.51 was reached on 09/22/25, a 52-week low of $10.14 was recorded on 04/07/25.
Levels Of Support And Resistance For CDTX Stock
The 24-hour chart illustrates a support level at 70.58, which if violated will result in even more drops to 65.69. On the upside, there is a resistance level at 78.00. A further resistance level may holdings at 80.53.
How much short interest is there in Cidara Therapeutics Inc?
A steep rise in short interest was recorded in Cidara Therapeutics Inc stocks on 2025-08-29, dropping by 36010.0 shares to a total of 2.15 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 2.19 million shares. There was a decline of -1.67%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 08, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $33 price target.
